Adults using a GLP-1 receptor agonist do not have increased risk for nonarteritic anterior ischemic optic neuropathy, according to data from a retrospective analysis published in Journal of Diabetes Science and Technology.
As Healio previously reported, a study published in JAMA Ophthalmology found adults attending Massachusetts Eye and Ear who were prescribed semaglutide (Ozempic/Wegovy, Novo Nordisk) had a higher risk for developing nonarteritic anterior ischemic optic neuropathy (NAION) than those using a non-GLP-1 receptor agonist. However, David C. Klonoff, MD, FACP, FRCP (Edin), Fellow